Research Associate @MSKCC Molecular Pharmacology Lab
Apr 29 • 8 tweets • 2 min read
Fresh out of press! 🧬🔬We are happy to share our latest work published in @CancerDiscovery! A thread🧵 Please, Enjoy and share! #CancerResearch, #PrecisionOncology #CancerTherapeuticsshorturl.at/F4qnr
Using the MultiON RAS inhibitor RMC-7977, we showed that signaling dynamics are dependent on the mutational status of RAS genes over isoform or tumor types: MAPK pathway is inhibited in Q61X and rebounds in G12X models,while AKT pathway is inhibited in G12X and unaffected in Q61X
May 19, 2020 • 5 tweets • 4 min read
What’s the difference between colon and lung? Not an easy question when it comes to #KRAS. Our work out today in @CD_AACR today describe a strategy to overcome resistance to KRAS G12C inhibition in CRC. @sloan_kettering@Albert0Bardelli@BardelliLabbit.ly/2ACWd7H👇👇👇
Molecular response to KRAS G12C inhibitors is different in CRC and NSCLC models. CRC models show quick MAPK pathway rebound